Health

Cardiolyse Issues Call for Action on Arrhythmia Risks following the Heart Disease Mortality Study

Posted by

admin

On July 15, 2025

Comments Off

Table of Contents

Cardiolyse, the premier AI-driven cardiac analytics company, reacts to a significant U.S. heart disease mortality study of a 450% increase in arrhythmia deaths since 1970. Cardiolyse is calling upon healthcare practitioners and the public to embrace sophisticated, automated ECG screening to identify arrhythmias at an early stage and reverse this lethal trend.

The American Heart Association study reveals a 66% reduction in overall death due to heart disease, led by improvement in preventing and treating heart attacks.

Chronic Heart Conditions Increasing Despite Fewer Heart Attacks

But the report also reveals a sudden increase in mortality from arrhythmias (up 450%), heart failure (up 146%), and hypertensive heart disease (up 106%) during the same time. As fewer Americans are dying from heart attacks, more are surviving – and dying from – chronic, frequently asymptomatic, heart disease.

CEO Normunds Daudiss Calls for Focus on Early Detection

The reduction in deaths due to heart attacks is a success story of the force of prevention and innovation. Now, as arrhythmias and heart failure increase, we need to shift attention to early detection and active management. Cardiolyse’s artificial intelligence-enabled ECG analysis enables us to catch at-risk patients before they develop symptoms, ushering in a new chapter in cardiovascular health.”

— Normunds Daudiss, CEO, Cardiolyse

AI-Enabled ECG Analysis by Cardiolyse Provides Real-Time Detection

Cardiolyse’s cloud-based solution leverages automated, AI-driven ECG analysis to deliver early, precise screening for arrhythmias like atrial fibrillation (AFib), a major contributor to stroke and heart failure.

Core features of Cardiolyse’s next-generation cardiac solution

Live AI-driven reporting on any ECG device data;
Automated identification of over 25 arrhythmia types with clinical-grade precision;
Personalized Risk Assessment and Wellness scores, e.g., Risk of Heart Disorders;
Web-based platform to facilitate remote 12-lead ECG point-of-care interpretation.

Cardiolyse’s Public Call to Action for Heart Health

As a call to action in response to the study results, Cardiolyse encourages individuals, clinicians, and policymakers to:

Make periodic heart rhythm screening a priority – particularly among people over 50 or with risk factors;
Embrace AI-based ECG solutions to facilitate the early identification of silent arrhythmias;
Empower patients with digital capabilities for home monitoring and data sharing with care teams without any hassle
Encourage preventive care to meet the increased workload of chronic cardiovascular diseases.

AI-Based ECG Screening Can Revolutionize Preventive Cardiology

“Harnessing AI for ECG analysis allows us to screen huge populations for heart risk quickly and accurately – translating data into prevention. The future of cardiovascular health is in smart technology that operates quietly in the background, warning us of threats we may otherwise overlook.” – adds the CEO of Cardiolyse.

Global Trust and a Decade of Clinical Validation Behind Cardiolyse

More than a decade of research and clinical validation, Cardiolyse’s platform is relied upon by healthcare professionals worldwide to provide predictive, personalized cardiac intelligence. The mission of the company is to bring cutting-edge heart health monitoring anywhere, anytime.

About Cardiolyse: AI Innovation in Predictive Cardiac Care

Cardiolyse is a digital health technology company with a cloud platform for predictive cardiac analytics based on AI, providing real-time remote ECG monitoring and individualized risk assessment for healthcare professionals and patients globally.

Get in Touch with Cardiolyse for Media, Partnerships, and Product Inquiry

For media inquiries, partnership opportunities, or product demonstrations, please contact:
Cardiolyse
Email: info@cardiolyse.com
Website: www.cardiolyse.com

Media Contact

Organization: Cardiolyse Oy

Contact Person: Susan Press

Website: https://cardiolyse.com/

Email: info@cardiolyse.com

Address: Haartmaninkatu 4

City: Helsinki

Country: Finland

Release Id: 15072530767